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Abstract
Background Glypican-3 (GPC3) is a new prognostic
factor after curative hepatectomy in patients with hepato-
cellular carcinoma (HCC), and the expression of GPC3 is
known to be associated with postoperative metastasis.
However, the role of GPC3 in patients with early HCC
remains unknown.
Methods We retrospectively studied 55 patients with
early HCC (total 99 nodules) who underwent initial hepa-
tectomy between 1995 and 2010. Clinicopathological fea-
tures and surgical outcomes were compared in relation to
GPC3 expression.
Results The GPC3-positive expression was seen in 28 of
55 patients (50.9 %) with early HCC (44 of 99 nodules).
The GPC3-positive expression was significantly associated
with hepatitis C virus (HCV) infection (P = 0.0019) and
with multiple early HCCs (P \ 0.0001). The 5-year dis-
ease-free survival rate was significantly lower in patients
with GPC3-positive early HCC (27 %) than in patients
with GPC3-negative early HCC (62 %, P = 0.0036). The
GPC3 expression was a significant independent prognostic
factor for disease-free survival. However, it showed no
significant difference in overall survival.
Conclusions The GPC3 expression is capable to be a new
prognostic factor for disease-free survival in patients with
early HCC.
Keywords GPC3  Early hepatocellular carcinoma 
Surgical outcome
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and the third most common cause of cancer-
related death worldwide [1]. Infections with hepatitis B
virus (HBV) or hepatitis C virus (HCV), which lead to
chronic liver disease and are often associated with cirrho-
sis, are the major risk factors for HCC.
Glypican-3 (GPC3) is a heparin sulfate proteoglycan
involved in migration, proliferation and modulation of cell
survival in several tissues [2–6]. Expression of GPC3 has
been observed in some embryonic tissues, including liver,
but it is silenced in the corresponding normal adult tissue
[7]. The GPC3 expression was also found to be higher in
72 % of advanced HCC tissues and was undetectable in
normal liver, cirrhotic liver or liver with focal lesions such
as dysplastic nodules and areas of hepatic adenoma (HA)
[6, 8–11]. The expression of GPC3 was also found to relate
with postoperative metastasis in advanced HCC patients
[12–14].
The role of GPC3 in patients with early HCC is still
unclear and it remains to be elucidated. This work was
undertaken to determine the role of GPC3 in early HCC
and, additionally, to evaluate its relation to outcomes of
patients with early HCC.
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Between 1995 and 2010, 55 consecutive patients with 99
tumors of early HCC who had undergone initial hepatec-
tomy at Tokyo Women’s Medical University Hospital were
retrospectively selected in the study. All 99 resected tumors
were pathologically diagnosed as early HCC. Of these 55
patients, 37 had solitary early HCC and 18 had multiple
early HCC (total 62 nodules; range 2–9 nodules/patient;
mean 3.5 ± 1.8 nodules/patient).
Diagnostic criteria
According to the classifications of the Liver Cancer Study
Group of Japan [15] and the International Consensus Group
for Hepatocellular Neoplasia in 2009 [16], the diagnosis of
early HCC consisted of: grossly, indistinct tumor margin
with size less than 2 cm in greatest diameter, and upon
histologic analysis, the varying combination of the fol-
lowing features: (1) increased cell density, with an
increased nuclear/cytoplasmic ratio and irregular thin-
trabecular pattern; (2) diffuse fatty change; (3) varying
numbers of portal tracts within the nodule (intratumoral
portal tracts); (4) early HCC cells involving the portal tract,
showing invasion by cancer cells with unremarkable cel-
lular atypia, which is a key point of histological differential
diagnosis from high-grade dysplastic nodules of the liver.
When the early HCC was seen multifocally, the patient was
given a diagnosis with multiple early HCCs. Patients with
nodule in nodule HCC (advanced HCC within early HCC)
were excluded in this study.
Demographic patient characteristics included in the
analysis are summarized in Table 1. The study protocol
conformed to the ethical guidelines of the World Medical
Association Declaration of Helsinki.
Immunohistochemistry
Immunohistochemical staining for GPC3 and Alfa-feto-
protein (AFP) were performed using formalin-fixed and
paraffin-embedded tissue sections. The primary monoclo-
nal antibodies used were anti-GPC3 (clone 1G12, Biomo-
saics, Burlington, VT) and anti-Alfa-fetoprotein (Dako,
Carpinteria, CA). Briefly, 4-lm sections from formalin-
fixed, paraffin-embedded tissue blocks were deparaffinized
in xylene and rehydrated through ethanol to water.
Endogenous peroxidase activity was blocked using 3 %
H2O2 in methanol for 15 min. Following heat-induced
epitope retrieval in 0.1 mol/L of citrate buffer at pH 6.0 in
a microwave for 20 min, the slides were incubated over-
night at 4 C with mouse monoclonal antibody specific for
GPC3 (clone 1G12, Biomosaics) diluted 1:100 and 1:50 for
AFP. After incubation with a rabbit antimouse secondary
antibody, a reaction was performed using the Envision Plus
detection system that contained biotin-free horseradish
peroxidase-labeled polymers (Dako, Carpinteria, CA). The
staining was visualized using 3,30-diaminobenzidine sub-
strate-chromogen solution and counterstained with hema-
toxylin. For GPC3, cytoplasmic and/or peri-canalicular
immunoreactivity were assessed. For AFP, cytoplasmic
immunoreactivity was assessed.
Immunohistochemically stained slides were indepen-
dently evaluated by 2 observers. Cases with significantly
discrepant interpretation were resolved by review of the 2
observers together. Staining for GPC3 (cytoplasmic and/or
Table 1 Correlation between GPC3 expression and clinicopatho-
logical features of early HCC patients
Clinicopathological
features





Age (years, mean ± SD) 65.5 ± 1.4 63.5 ± 1.4 0.3338
Gender
Male 18 18 0.7757
Female 10 9
HBs antigen
Positive 1 6 0.038
Negative 27 21
HCV antibody
Positive 27 17 0.0019
Negative 1 10
Cirrhosis
Present 16 18 0.3157
Absent 12 9
Child-Pugh grade
Child A 23 24 0.4437
Child B or C 5 3
ICG R15 (%, mean ± SD) 18.0 ± 1.5 16.6 ± 1.5 0.5095
AFP (ng/mL, mean ± SD) 74.1 ± 17.7 42.2 ± 17.7 0.2086
PIVKA-II (mAU/L,
mean ± SD)
22.5 ± 5.9 14.4 ± 5.6 0.3422
Number of early HCC
Solitary 12 25 \0.0001
Multiples 16 2
Resection procedures
Sectionectomy or larger 19 16 0.5076
Segmentectomy or smaller 9 11
Tumor size (cm,
mean ± SD)
1.9 ± 0.2 2.0 ± 0.2 0.4809
GPC3 Glypican3, HCC hepatocellular carcinoma, HBs antigen hep-
atitis B surface, HCV hepatitis C virus, ICGR15 indocyanine green
retention rate at 15 min, AFP alpha-fetoprotein, PIVKA-II protein
induced by vitamin K absence and antagonist-II
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peri-canalicular) was classified as positive when at more than
10 % of the tumorous population. Patients with multiple
early HCC were counted as positive when one of the nodules
expressed GPC3. Staining for AFP was classified as positive
when at more than 6 % of the tumorous population [17].
Statistical analysis
Statistical analysis was performed using SAS software (version
9.1.3; SAS Institute, Inc., Cary, NC). Categorical variables
were determined using the Chi squared test as appropriate.
Continuous variables were expressed as the mean ± standard
deviation and were determined using the student t test. Both
disease-free survival (DFS) and overall survival (OS) rates
were estimated using the Kaplan–Meier method and differ-
ences in survival rate were compared using the log-rank test or
Wilcoxon test. Significant variables from the univariate anal-
ysis were entered in the multivariate analysis, which was per-
formed using the Cox multivariate proportional hazards model
with forward stepwise selection. The P values of\0.05 were
taken to indicate statistical significance.
Results
GPC3 expression in patients with early HCC
Among 55 patients, GPC3 expression was positive in 28
(50.9 %) (44 of 99 nodules, 44.4 %) and negative in the
remaining 27 (49.1 %) (55 of 99 nodules, 55.6 %). The
surrounding non-cancerous parenchyma stained negative
for GPC3 (Fig. 1c). The GPC3-positive cancer cells could
be seen invading the interstitial space of residual portal
tracts in the cancerous area (Fig. 1d).
Of the 28 patients with GPC3-positive expression, 12 had
solitary early HCCs and 16 had multiple early HCCs. With
regard to the immunohistochemistry staining pattern of the
28 patients with positive expression, 4 showed a diffused
mix pattern (cytoplasmic and pericanalicular) (Fig. 2a, b), 4
showed a peri-canalicular pattern (Fig. 2c) and 20 showed a
diffused cytoplasmic staining pattern (Fig. 2d).
AFP expression in patients with early HCC
AFP-negative expression was observed in all 55 patients
with 99 nodules.
Correlation between GPC3 expression
and clinicopathological variables in patients with early
HCC
GPC3-positive early HCCs were more frequent than
GPC3-negative early HCCs in patients with HCV infection
(P = 0.0019) and in patients with multiple early HCC
(P \ 0.0001). There was no significant correlation between
GPC3 expression and liver cirrhosis, Child-Pugh grade,
ICGR15, AFP level, PIVKA-II level, operation procedures
and tumor size (Table 1).
Fig. 1 Early HCC and GPC3
expression. a Early HCC with
diffuse fatty changes. Portal
tract invasion (arrow head)
(H&E, 910). b Cancer cells
invade the stromal of the portal
tract (arrow heads) (VBHE,
920). c Positive expression of
GPC3 in cancerous areas but
negative in non-cancerous areas
(910). d Higher magnification
shows a GPC3-positive peri-
canalicular pattern and invasion
of GPC3-positive cancer cells to
the stromal of the portal tract
(arrow heads) (920)
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Prognostic significance of GPC3 expression
Univariate analysis revealed that HBV-negative (P =
0.0176), HCV-positive (P = 0.0053), GPC3 expression
(P = 0.0036), patients with multiple early HCC (P =
0.0003) and PIVKA-II C 20 mAU/ml (P = 0.0385) were
significantly associated with a high risk of recurrence after
hepatectomy. Multivariate analysis indicated that HCV
infection (risk ratio, 5.126; 95 % CI: 1.461–17.990;
P = 0.0107), GPC3 expression (risk ratio, 2.606; 95 % CI:
1.170–5.802; P = 0.0190) and multiple early HCC (risk
ratio, 2.785; 95 % CI: 1.172–6.619; P = 0.0204) were
independent prognostic factors for DFS after hepatectomy
(Table 2). When survival analysis was performed, GPC3-
positive early HCCs (5-year DFS rate 27 %) showed
decreased DFS compared with GPC3-negative early HCCs
(5-year DFS rate 62 %) (P = 0.0036) (Table 2; Fig. 3).
For OS, both univariate and multivariate analyses
revealed that PIVKA-II C20 mAU/ml and presence of
recurrence were significant prognostic factors after hepa-
tectomy. The GPC3 expression, however, showed no sig-
nificant difference in OS (Table 3).
Recurrence pattern in patients with early HCC
Among 55 patients with early HCC, 33 patients (43 nod-
ules) had recurrence in the remnant liver after hepatec-
tomy. Of those, 27 patients with 34 nodules underwent
radiofrequency ablation (RFA) as all 34 nodules showed
low density in the arterial phase CT scan with mean tumor
size 1.4 ± 0.1 cm. As for the remaining 6 patients, 3
patients with 3 nodules underwent transcatheter arterial
chemoembolization (TACE) and 3 patients with 6 nodules
underwent second hepatic resection as those nodules
showed high density on the arterial phase CT scan with a
mean tumor size 2.4 ± 0.2 cm. In the 3 patients with 6
nodules who underwent second hepatic resection, the
GPC3 expression was positive in all nodules.
Discussion
Recently, GPC3 has been reported to be a new prognostic
factor after curative hepatectomy in patients with HCC,
and the expression of GPC3 was also found to be associ-
ated with postoperative metastasis in HCC patients
[12–14]. There have been a few previous reports of the
expression of GPC3 in early HCC [18, 19]. Di Tommaso
et al. [18] reported that 11 of 17 patients with early HCC
(64.7 %) showed positive GPC3 expression. However,
there have been no previous reports of outcomes after
hepatectomy or clinical features in relation to GPC3
expression in patients with early HCC. In our study, GPC3
expression was found in 28 (50.9 %) of 55 early HCC
patients, and GPC3-positive expression was significantly
more frequent in patients with HCV and multiple early
Fig. 2 GPC3 immunostaining
patterns: a, b Mixed type
(cytoplasmic and peri-
canalicular) (920). c Peri-
canalicular type (arrow heads)
(940). d Cytoplasmic type
(arrows) (940)
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HCC. Furthermore, GPC3-positive early HCC was an
independent significant prognostic factor for poor DFS in
patients with early HCC.
Early HCC is characterized as pre-invasive or early
invasive cancer with a mild deviation of the clinicopatho-
logical features from chronic liver disease. The patholog-
ical definition of early HCC has been reported by the Liver
Cancer Study Group of Japan [15]. However, differential
diagnosis of early HCC and dysplastic nodules is
sometimes difficult on the basis of pathological findings.
The GPC3 is a useful immunohistochemical marker for
distinguishing early HCC and small hepatic nodules such
as dysplastic nodules, since GPC3 was found to express in
early HCC but not in small hepatic nodules [10, 20]. In
addition, Sakamoto et al., reported that a combination of
the three-marker panel consisting of GPC3, glutamine
synthetase (GS) and heat shock protein 70 (HSP70) can
raise the accuracy of distinguishing between dysplastic
Table 2 Prognostic factors for
disease free survival (DFS) by
univariate and multivariate
analysis in patients with early
HCC
HCC hepatocellular carcinoma,
HBs antigen hepatitis B surface,
HCV hepatitis C virus, GPC3
Glypican3, ICGR15 indocyanine
green retention rate at 15 min,
AFP alpha-fetoprotein, PIVKA-
II protein induced by vitamin K
absence and antagonist-II, 95 %
CI 95 % confidence interval
Variables Number Univariate analysis Multivariate analysis
1-year 3-year 5-year P value Relative
risk
95 % CI P value
Age
B64 24 95.2 85.2 75.2 0.1053
[64 31 93.1 82.7 72
Gender
Male 36 79.9 51.7 43 0.4595
Female 19 87.5 68.8 32.4
HBsAg
Negative 48 78.8 51 38.5 0.0176 1.136 0.186–6.944 0.8905
Positive 7 87.5 72.9 54.7 1
HCV
Negative 11 87.5 65.6 43.8 0.0053 1
Positive 44 62.5 51.1 39.4 5.126 1.461–17.990 0.0107
Child-Pugh grade
Child A 47 84.1 62 46.5 0.226
Child B/C 8 75 57.7 37.5
Cirrhosis
Absent 21 91.4 84.5 77.5 0.1934
Present 34 92 85.4 71.2
GPC3 expression
Negative 27 95.8 87.1 62 0.0036 1
Positive 28 68 42. 6 27 2.606 1.170–5.802 0.019
Number of early HCC
Solitary 37 90.2 75.8 67.6 0.0003 1
Multiple 18 60 26.7 13.3 2.785 1.172–6.619 0.0204
ICG R15
\15 % 21 93.3 84.9 76.4 0.1322
C15 % 34 90.9 77.8 69.1
AFP (ng/mL)
\50 41 93.8 85.1 74.8 0.2803
C50 14 85.7 68.6 45.7
PIVKA-II (mAU/L)
\20 37 94.1 89.2 78.6 0.0385 1




35 96.6 79.3 68.6 0.2812
Segmentectomy or
smaller
20 94.7 78.6 71.5
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nodules (DN) and early HCC [21–23]. Therefore, GPC3 is
not only a useful marker for differential diagnosis, but also
an indication for treatment of early HCC since GPC3-
positive patients have a high recurrence rate after
hepatectomy.
It is well known that AFP is produced in advanced HCC.
Both AFP and GPC3 are oncofetal genes; common factors
may regulate their expressions in similar patterns [24].
However, Fujioka et al., reported that AFP expression was
not found in 15 well-differentiated HCCs (early HCC) [17].
In the present study, AFP expression was observed to be
negative in all 55 patients. Therefore, GPC3 is a useful
marker for the diagnosis of early HCC.
Clinically, patients with early HCC have favorable
surgical outcomes with better survival rate after hepatec-
tomy [25, 26]. However, intrahepatic recurrence due to
secondary primary HCC is often seen even in patients with
early HCC [27, 28]. Takayama et al. [25] reported that the
5-year recurrence-free rate was 53 % in patients with early
HCC. However, the report did not evaluate prognostic
factors for DFS. In the present study, HCV infection,
multiple early HCC and GPC3-positive expression were
significant independent prognostic factors for DFS in
patients with early HCC. The GPC3 expression was
observed more frequently in patients with HCV infection
and with multiple early HCCs. Therefore, early HCC
patients with GPC3-positive expression should be fol-
lowed-up after hepatectomy because they have a higher
recurrence rate due to secondary primary HCC.
Intrahepatic metastasis and multicentric occurrence of
HCC have been known as recurrence patterns of HCC.
Intrahepatic metastasis of HCC is caused by various
degrees of vascular invasion in advanced HCC. However,
multicentric recurrence of HCC is caused by secondary
primary cancer due to chronic hepatitis or cirrhosis. In our
study, 33 of 55 patients with early HCC recurred due to
multicentric occurrence because no vascular invasion of
HCC was seen in all of the patients.
Prolonged active chronic inflammation and extensive
fibrosis due to HCV are responsible for the development of
multiple occurrence of HCC [29]. Highly GPC3 expression
rate has also been reported in HCV-related HCC patients
[30]. In our study, the presence of GPC3 expression was
observed more frequently in early HCC patients with HCV
infection and those with multiple tumors. Patients with
these characteristics tended to result in higher carcino-
genesis of early HCC. Highly incidence of recurrence in
GPC3 positive early HCC was also observed. These were
attributed to the hepatocarcinogenesis in HCV-related
patients depending on a persistent active inflammation then
followed thereafter by cirrhosis. Such persistent active
inflammation may cause continuous necrosis and regener-
ation of hepatocytes [31]. The GPC3 expression on the cell
membrane of proliferate hepatocyte promotes the growth
of HCC by stimulating the canonical Wnt pathway during
malignant transformation [32] that may be a crucial
mechanism to accelerate cancer occurrence in the remnant
liver.
Recently, the expression of GPC3 has been evaluated as
a potential candidate for cancer immunotherapy in patients
with advanced HCC. Therapeutic implications of GPC3-
derived peptide vaccination have been demonstrated to be
well tolerated and to improve overall survival in patients
with advanced HCC [33, 34]. Thus, GPC3-derived peptide
vaccination may be required as an adjuvant treatment
because 28 of 55 patients (50.9 %) were GPC3-positive
and there was a high recurrence rate in such GPC3-positive
early HCCs. Therefore, further study with GPC3-derived
peptide vaccination to prevent recurrence after treatment
for patients with early HCC is required.
Early cancer cells show heterogeneous proliferation on
pathological findings. Recently, genetic differences
between early HCC and very early HCC have been
reported [35]. In our present study, GPC3 expression was
not positive for homogeneity, but positive for heterogene-
ity. However, when the GPC3-positive cells accounted for
at least 10 % of cancer cells, the rate of multiple early HCC
and the recurrence rate after hepatectomy were high.
Therefore, GPC3-positive early HCC cells may spread
even if the pathological characteristics indicate early HCC.
Vascular invasion and intrahepatic metastasis of HCC
are the well-known characteristics and prognostic factors
after curative hepatectomy in HCC patients. However,
there are no previous reports of prognostic factors of
patients with early HCC. In our present study, DFS of
Fig. 3 DFS vs GPC3 expression: Decreasing disease-free survival in
GPC3-positive early HCC patients
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GPC3-positive early HCC patients was significantly worse
than that of GPC3-negative early HCC patients. However,
OS of GPC3-positive early HCC patients showed no sig-
nificant difference than GPC3-negative patients. Because
hepatic recurrences were mostly found small and early
HCCs from image detection, appropriate treatments for
them had been immediately performed. In conclusion,
GPC3 participate in the early stage of hepatocarcinogenesis
and are capable of being a new prognostic factor for DFS in
patients with early HCC.
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